MannKind (NASDAQ: MNKD) is expected to release $16.08 million in sales for this ongoing quarter by equities analysts on 5th May. They have $16.24 million lowest estimates and $16.95 million highest. The firm posted $16.24 million in sales last year in this quarter, indicating a 1% negative annualized growth rate.
On Monday, the company started from $4.15 with a market cap being $1.03 billion. Their lowest in 1 year is $0.91 while the highest is $6.25. They have a -19.78 PE ratio and 2.28 beta. Their 50 day rolling average is $4.42 while the 200 day is $3.25.
According to their 25th February report, they had a quarterly EPS of $0.06, missing the $0.03 consensus estimate by roughly $0.03. Their quarterly revenue was $18.44 million that exceeded the $16.13 estimate.
Market Undertakings of MNKD Stock
Zacks upped the rating of MNKD shares to ‘hold’ from ‘sell’. Oppenheimer reassigned the rating of ‘buy’ and allotted it a price objective of $7. HC Wainwright promoted it to $6.5 from $2.50. SVB Leerink increased it to $5 from $3 and gave a rating of ‘outperform’. BTIG Research lifted it to $8 from $ and gave a rating of ‘buy’. The company has the consensus ‘buy’ recommendation with a $5.70 price objective.
Manufacturers LIC upgraded their holdings on MannKind stock by almost 2% and own shares priced at $420,000. Cambridge Research Advisors promoted their stake by nearly 7.4% and own shares valued at $126,000. Hunter Investment Management lifted their position by approximately 23.9%, owning $49,000 worth shares. High Tower upped their position by roughly 29.5% and own shares priced at $43,000. Virtu Financial promoted their stake by nearly 13% and their own shares valued at $145,000. Hedge funds and institutional investors own 29.60% MannKind stock.
Mannkind happens to be a biopharmaceutical firm which deals with the selling and development of endocrine and diseases of lungs across the US.
